Brief: Lumibird FY EBITDA Up At EUR 32.6 Million

Lumibird SA

17/03/2022 17:10

March 17 (Reuters) - Lumibird SA  LBIRD.PA :
    * 2021 EARNINGS: INITIAL TARGET ACHIEVED FOR AN
EBITDA/REVENUE
RATIO OF OVER 20%
    * CONSOLIDATED FULL- YEAR REVENUES CAME TO €162.5M IN 2021,
UP 28%
BASED ON REPORTED DATA
    * FY EBITDA UP 25% PROFORMA TO €32.6M (20.1% OF REVENUES)
    * CONTINUED INCREASE IN PROFITABILITY FOR THE MEDICAL
DIVISION,
DRIVEN BY THE SUCCESSFUL INTEGRATION OF ELLEX
    * FY NET INCOME EUR 13.9 MILLION
    * FINANCIAL POSITION IS ENABLING THE GROUP TO MAINTAIN ITS
FINANCIAL FLEXIBILITY AND ITS CAPACITY TO CONTINUE FINANCING ITS
AMBITIONS FOR GROWTH
    * SINCE THE START OF 2022, LUMIBIRD HAS RECORDED A GOOD
LEVEL OF
ORDERS, FOR BOTH PHOTONICS, ACROSS ITS THREE SEGMENTS, AND THE
MEDICAL BUSINESS
    * HAS ALSO BEEN RELATIVELY UNAFFECTED BY THE GEOPOLITICAL
TENSIONS
IN UKRAINE AND RUSSIA, WHETHER IN TERMS OF ITS SALES (LESS THAN
2% OF REVENUES), ITS PURCHASES (SOURCING SECURED FOR 2022) OR
ITS CLIENT RISK
    * OPERATION TO ACQUIRE SAAB'S RANGEFINDER BUSINESS ASSETS IN
SWEDEN IS MOVING FORWARD IN LINE WITH SCHEDULE SET AND IS
EXPECTED TO BE COMPLETED DURING THE SECOND QUARTER OF 2022
    * IS ABLE TO CONFIRM ITS TARGET FOR ITS REPORTED REVENUES TO
EXCEED €250M IN 2023

Source text for Eikon:  ID: 
Further company coverage:  LBIRD.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))